BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Novome gets $33M to back gut-focused chronic disease drive
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Novome gets $33M to back gut-focused chronic disease drive
Jan. 7, 2020
By
Michael Fitzhugh
No Comments
Novome Biotechnologies Inc., a startup developing a hyperoxaluria therapy based on controlled colonization of the gut with engineered bacteria, has landed a $33 million series A financing and appointed former Achaogen Inc. chief Blake Wise as CEO.
BioWorld
Financings
Newco news
Endocrine/metabolic